Access CEA
System, Test, Carcinoembryonic Antigen. 510(k) K223921, from Beckman Coulter, Inc. (Chaska, MN). Product code DHX, class 2.
As of Nov 20, 2026, K223921 is an FDA 510(k) held by Beckman Coulter, Inc., substantially equivalent on Sep 22, 2023 after 267 days, with no recalls tied to it in FDA's recall database.
- Review time: 267 days
- Recalls: 0
The Access CEA assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of Carcinoembryonic Antigen (CEA) levels in human serum, using the Access Immunoassay Systems. CEA measured by the Access Immunoassay Systems is used as an aid in the management of cancer patients in whom changing CEA concentrations have been observed.
- Modification To Access Cea Reagents for Use On The Access Immunoassay Analyzer, Models 33200, 33205, 33209, 33206K991707 · Beckman · Jun 1, 1999
- Access Cea Reagents On The Access Immunoassay Analyzer Model 33200, 33205, 33206 & 33209K981985 · Beckman Coulter, Inc. · Sep 24, 1998
- VITROS Immunodiagnostic Products CEA Reagent PackK231517 · Ortho Clinical Diagnostics · Aug 23, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Dec 29, 2022
- Review panel
- Immunology
- Regulation
- 21 CFR 866.6010
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files